169 related articles for article (PubMed ID: 17270269)
1. Reduced expression of FLIP SHORT in bone marrow of low risk myelodysplastic syndrome.
de Melo Campos P; Traina F; da Silva Santos Duarte A; Lorand-Metze I; Costa FF; Saad ST
Leuk Res; 2007 Jun; 31(6):853-7. PubMed ID: 17270269
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle and apoptosis regulatory gene expression in the bone marrow of patients with de novo myelodysplastic syndromes (MDS).
Economopoulou C; Pappa V; Papageorgiou S; Kontsioti F; Economopoulou P; Charitidou E; Girkas K; Kapsimali V; Papasteriadi C; Tsirigotis P; Papageorgiou E; Dervenoulas J; Economopoulos T
Ann Hematol; 2010 Apr; 89(4):349-58. PubMed ID: 19813013
[TBL] [Abstract][Full Text] [Related]
3. Expression of FLIP(Long) and FLIP(Short) in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis.
Benesch M; Platzbecker U; Ward J; Deeg HJ; Leisenring W
Leukemia; 2003 Dec; 17(12):2460-6. PubMed ID: 14562111
[TBL] [Abstract][Full Text] [Related]
4. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.
Qi H; Xiao L; Lingyun W; Ying T; Yi-Zhi L; Shao-Xu Y; Quan P
Ann Hematol; 2006 Feb; 85(2):95-101. PubMed ID: 16328478
[TBL] [Abstract][Full Text] [Related]
5. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of APAF-1 in low-risk myelodysplastic syndrome: a possible role in the pathophysiology of myelodysplasia.
Benites BD; Traina F; Duarte Ada S; Lorand-Metze IG; Costa FF; Saad ST
Eur J Haematol; 2010 Jun; 84(6):525-30. PubMed ID: 20345447
[TBL] [Abstract][Full Text] [Related]
7. Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.
Gianelli U; Fracchiolla NS; Cortelezzi A; Pellegrini C; Savi F; Moro A; Grimoldi MG; Deliliers GL; Coggi G; Bosari S
Ann Hematol; 2007 Mar; 86(3):185-9. PubMed ID: 17124585
[TBL] [Abstract][Full Text] [Related]
8. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
9. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
[TBL] [Abstract][Full Text] [Related]
10. Evi-1 and MDS1-Evi-1 genes in pathogenesis of myelodysplastic syndromes and post-MDS acute myeloid leukemia.
Xu K; Wang L; Hao Y; Shao Z; Meng Q; Li K; Chao H; Tang K; Wang L
Chin Med J (Engl); 1999 Dec; 112(12):1112-8. PubMed ID: 11721451
[TBL] [Abstract][Full Text] [Related]
11. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
Maratheftis CI; Bolaraki PE; Voulgarelis M
Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
13. Expression dynamics of drug resistance genes, multidrug resistance 1 (MDR1) and lung resistance protein (LRP) during the evolution of overt leukemia in myelodysplastic syndromes.
Kurata M; Hasegawa M; Nakagawa Y; Abe S; Yamamoto K; Suzuki K; Kitagawa M
Exp Mol Pathol; 2006 Dec; 81(3):249-54. PubMed ID: 16566920
[TBL] [Abstract][Full Text] [Related]
14. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
Monreal MB; Pardo ML; Pavlovsky MA; Fernandez I; Corrado CS; Giere I; Sapia S; Pavlovsky S
Cytometry B Clin Cytom; 2006 Mar; 70(2):63-70. PubMed ID: 16470534
[TBL] [Abstract][Full Text] [Related]
15. Analysis of apoptosis regulatory genes expression in the bone marrow (BM) of adult de novo myelodysplastic syndromes (MDS).
Economopoulou C; Pappa V; Kontsioti F; Papageorgiou S; Kapsimali V; Papasteriadi C; Economopoulou P; Papageorgiou E; Dervenoulas J; Economopoulos T
Leuk Res; 2008 Jan; 32(1):61-9. PubMed ID: 17597205
[TBL] [Abstract][Full Text] [Related]
16. Limited numbers of apoptotic cells in fresh paraffin embedded bone marrow samples of patients with myelodysplastic syndrome.
Brada SJ; van de Loosdrecht AA; Koudstaal J; de Wolf JT; Vellenga E
Leuk Res; 2004 Sep; 28(9):921-5. PubMed ID: 15234568
[TBL] [Abstract][Full Text] [Related]
17. [Abnormal polarization of T lymphocyte induces negative hematopoietic regulation in myelodysplastic syndromes].
Wu LY; Li X; Chang CK; Ying SX; Pu Q
Zhonghua Xue Ye Xue Za Zhi; 2007 Aug; 28(8):549-54. PubMed ID: 18078133
[TBL] [Abstract][Full Text] [Related]
18. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia.
Keith T; Araki Y; Ohyagi M; Hasegawa M; Yamamoto K; Kurata M; Nakagawa Y; Suzuki K; Kitagawa M
Br J Haematol; 2007 May; 137(3):206-15. PubMed ID: 17408459
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
Bernasconi P
Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
[TBL] [Abstract][Full Text] [Related]
20. Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome.
Tourneur L; Delluc S; Lévy V; Valensi F; Radford-Weiss I; Legrand O; Vargaftig J; Boix C; Macintyre EA; Varet B; Chiocchia G; Buzyn A
Cancer Res; 2004 Nov; 64(21):8101-8. PubMed ID: 15520222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
